Aegis Capital reiterated its ‘Buy’ rating and $21 price target on shares of Akebia Therapeutics (NASDAQ: AKBA). The biopharmaceutical company recently announced financial results for the fourth quarter and full year ended December 31, 2016, though Aegis focused on the company’s clinical trials and collaboration agreements for the reiteration. As reported in Akebia’s earnings release, full-year 2016 highlights include: the initiation of the global phase 3 INNO2VATE program to evaluate vadadustat in dialysis-dependent patients with anemia associated with chronic kidney disease (CKD); entered into a collaboration with Otsuka Pharmaceutical Co., Ltd in which the companies equally share the costs of developing and commercializing vadadustat in the U.S. and the profits from sales of vadadustat following FDA approval; signed an exclusive agreement with Janssen Pharmaceutica, NV, a Johnson & Johnson company, to license HIF product candidates and access an extensive library of HIF compounds that may have applications across multiple therapeutic areas; prevailed in two patent disputes through the European Patent Office; and published positive phase 2b study results in non-dialysis dependent chronic kidney disease patients in Kidney International.
To view the full press release, visit: http://nnw.fm/7tuXz
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. Akebia’s lead product candidate, vadadustat, is an oral investigational therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia’s global phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia associated with chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing. For more information, please visit our website at www.akebia.com.
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer